Q-omics provides the consensus-scored KIF21B profile across patient tissues and cancer cell-line models. KIF21B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KIF21B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, KIF21B RNA expression shows 19,555 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where KIF21B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF21B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF21B survival associations across molecular data types. KIF21B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF21B RNA expression–survival associations across cancer types. High KIF21B expression shows unfavorable associations in UVM and LUSC, but favorable associations in HNSC, UCS, LGG and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KIF21B RNA expression.
This table summarizes KIF21B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KIF21B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF21B shows lower tumor expression in LUSC and higher tumor expression in KIRC, COAD, HNSC, STAD and LIHC. The KIRC box plot shows higher KIF21B RNA expression in tumor versus normal tissue (log2 FC = +1.018, t-test p < 0.001).
This table shows molecular features associated with KIF21B in patient tissues and cancer cell lines. In patient samples, KIF21B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF21B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
